Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.

Content Provider	Europe PMC
Author	Navarini, Luca Currado, Damiano Costa, Luisa Tasso, Marco Chimenti, Maria Sole Caso, Francesco
Copyright Year	2020
Abstract	AbstractIn recent years, different studies have shown in psoriatic arthritis (PsA), the pathogenetic role of multiple cytokines other than tumor necrosis factor-α, such as interleukin-17 (IL-17), and IL-23 and dysfunction of Janus kinase (JAK)-signal family pathway. These molecules also represent the target of recently developed biologic (bDMARDs) and targeted synthetic disease modifying antirheumatic drugs (DMARDs) (tsDMARDs) currently investigated in several Phase II and III randomized controlled trials (RCTs). This review examines the therapeutic efficacy and safety of most recent developed IL-17, IL-23 and JAK inhibitors and highlights how these new PsA therapies are going to revolutionize the management of PsA in the next few years. Ongoing RCTs of these molecules in PsA are also described. Available literature on new anti-IL-17 and anti-IL-23 agents and JAK inhibitors demonstrates the potential role of these molecules as effective therapeutic strategies across multiple PsA clinical domains, along with an acceptable tolerability and safety profile, thus expanding the treatment options available for PsA patients. Of note, other molecules are under investigation, and among those, potential therapeutic strategies seem to be represented by single antibodies blocking simultaneously two cytokines, the agents inhibiting mammalian target of rapamycin (mTOR), receptor retinoic acid receptor-related orphan receptor gamma (RORγt), A3 adenosine receptor (A3 AR), and K+ channel voltage channel inhibitors. Remarkable progress has been made in PsA pharmacotherapy, and novel bDMARDs targeting IL17A and tsDMARDs (JAK-inhibitors) represent promising therapies. More clinical trials are needed to better characterize the efficacy and safety profile of these therapeutic agents in PsA treatment.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7679354&blobtype=pdf
Page Count	16
Journal	Journal of Experimental Pharmacology [J Exp Pharmacol]
Volume Number	12
PubMed Central reference number	PMC7679354
PubMed reference number	33235521
e-ISSN	11791454
DOI	10.2147/jep.s265633
Language	English
Publisher	Dove
Publisher Date	2020-11-16
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2020 Navarini et al.
Subject Keyword	bDMARDs filgotinib IL-17 inhibitors IL-23 inhibitors JAK-inhibitors psoriatic arthritis tofacitinib tsDMARDs upadacitinib
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Molecular Medicine Pharmacology